Overview on Advanced Drug Candidates
Hutchison MediPharma's development activities are focused on two target therapeutic areas: auto-immune/inflammatory disorders and oncology. Currently, Hutchison MediPharma has anti-inflammatory and anti-cancer drug candidates in the US and Chinese clinical trials and a pipeline of early stage leads. The discovery portfolio consists of botanical candidates, semi-synthetic natural product drugs, and synthetic single chemical entity projects. Currently, Hutchison MediPharma has obtained FDA approval to conduct Phase I/II and Phase II clinical trials in the US on two botanical drug candidates: HMPL-002, a radiosensitiser for the treatment of head and neck, lung and oesophageal cancers in combination with radiotherapy; and HMPL-004, a proinflammatory cytokine inhibitor for the treatment of Crohn's Disease ("CD"). HMPL-002 and HMPL-004 are also being tested both in research and proof of concept trials in China to expand the range of usage. In addition, we have one further EGFR/VEGFR inhibitor oncology drug candidate in pre-clinical studies assessing safety and efficacy.
